Executive Profiles

Patrick Soon-Shiong, the billionaire biotech entrepreneur and owner of NantWorks, a network of health startups, discusses his companies’ COVID-19 vaccine candidate and its “fighting chance” to outsmart the virus’s hidden tricks through merging supercomputing and modernized DNA delivery.

Former physician and clinical researcher Antony Loebel, now president and CEO of Sunovion Pharmaceuticals, discusses his career-long mission to advance novel treatments for patients suffering from serious and underserved CNS disorders.

Pharm Exec speaks with Arndt Rolfs, CEO and founder of CENTOGENE, who discusses his company’s rise from a small genetic diagnostics startup to a global organization focused on advancing the understanding of the pathophysiology of rare hereditary diseases.

Pharm Exec presents the diverse stories of 11 rising biopharma managers.

For Sandra Horning, this year's Healthcare Businesswomen’s Association Woman of the Year, harnessing the patient experience has been the driving force in a career-spanning-and service-focused-mission to fight disease and accelerate the delivery of new medicines.

AstraZeneca’s Habib Bennaceur talks about the key transitions in his career-from local to global-and his current role in positioning AZ’s Farxiga as a drug with the potential to impact the lives of both patients with and without type 2 diabetes.

Banks Bourne of Tanner Pharma Group talks about the organization's role in delivering access initiatives for products not commercially available in many parts of the world.

Philipp Maerz, CEO of Allergopharma talks about how the company has evolved, his recent transition to CEO, and how he plans to expand in the allergy treatment market.

Rob Biederman, co-CEO of Catalant Technologies, on why biopharma employees should consider a new career path.

Veteran pharma leader Jay Galeota shares learnings and perspectives from an off-the-beaten-path career rise-one driven today by a mission to align the industry’s risk-taking approach across the entire drug life cycle.

Fabrice Chouraqui, former president of Novartis Pharmaceuticals US, shares what he learned about the digital landscape of pharma during his tenure with the company.

Ken Shimokawa, Founder and General Partner of G4S Capital, shares insights into what venture capitalists look for when evaluating emerging biopharmaceutical opportunities.

Natalie Douglas talks about her experience in the area of managed and expanded access and her new venture, RareiTi.

Leela Barham talks to Dr. Brian O’Rourke, outgoing President and Chief Executive Officer of the Canadian Agency for Drugs and Technologies in Health (CADTH), about his 11 in years in the role.

Led in part by its new head of the Americas business, Sebastian Guth, Bayer went all in in 2019 on expanding pursuits in science and discovery, striking deals with 11 digital health startups and upping investment in disease-detection programs and patient engagement and education.

AstraZeneca's Joris Silon outlines the company's efforts in CVRM (Cardiovascular, Renal and Metabolism) and the potential impact on type-2 diabetes and chronic kidney disease of SGLT2 inhibitors such as Forxiga.

Hari Pujar, chief technology officer of Spark Therapeutics, discusses the unique manufacturing and scale-up challenges involved with cell and gene therapy production.

Korn Ferry's Dr. Paul Pospisil talks to HBSHAA's Michael Wong about why biopharma employees should be excited about the industry's prospects.

Lundbeck executive Taj Bhardwaj talks about the differing mindsets necessary to lead local and global-level market access strategy in pharma-and how his current company is committed to stay in the fight to advance new treatments and break down stigmas in mental health.

Amy Mahery, last month appointed Global Head of Market Access and Pricing of the healthcare business of Merck KGaA, Darmstadt, Germany, discusses her key priorities and how she will draw on her multi-faceted industry experience to approach the challenges ahead.

Aiforia Technologies CEO Kaisa Helminen talks about the benefits of pharma embracing digital technologies, especially AI-assisted image analysis in the field of histopathology.

Pharm Exec chronicles the journey of gene therapy visionary R. Jude Samulski, whose work unraveling the mysteries of adeno-associated virus continues to fuel new hopes in transforming drugs for rare disease.

Sebastian Guth, President of Pharmaceuticals, Americas Region for Bayer, shares the company's long-term vision.

Michael Wong speaks to Dr. Marc Grodman about leading BioReference, his new role as CEO of Genosity, and the future of digital transformation.

Jennifer Buell, chief operating officer at Agenus, discusses the need for additional immunotherapies and combination strategies in cancer-building on learnings from the first wave of immune checkpoint inhibitors.

Tina Tianning Yu, Chief Executive Officer of Mevion Medical Systems, talks about engaging with China's pharma market and laying the foundations for success in 2020 and beyond.

French independent pharma Servier Group, led by president Olivier Laureau, is uniquely positioned to capitalize on new opportunities for expansion and stay true to its R&D and patient-focused mission.

Corey McCann, president and CEO of Pear Therapeutics, discusses how the prescription digital therapeutics space has evolved in a decade from disruptive concept to an exciting, growing market.

Pharm Exec speaks to Katya Svoboda, Taneesha Chawla, and Tanvi Ahuja about the growing practice of applying AI and machine learning in value-based and outcomes-based contracts.

Bernhardt Zeiher, Chief Medical Officer of Astellas discusses how the company transitioned from a traditional R&D approach to a platform approach, the need for innovation models to change in pharma, and the impact academia has on drug development.